CBIH Builds Cannabinoid-Psilocybin Research Platform for PTSD, Targeting Memory and Emotional Regulation Pathways
Key Insights
Cannabis Bioscience International Holdings (search) (CBIH) announced completion of patent-related work exploring cannabinoids and psilocybin for PTSD (search), targeting trauma biology, memory, and emotional regulation.
Approximately 13 million U.S. adults experience PTSD (search) annually, with many cases undiagnosed or untreated, according to the U.S. Department of Veterans Affairs' National Center for PTSD.
The company's scientific framework posits that cannabinoids may support stress response and sleep pathways, while psilocybin shows potential in neuroplasticity and fear-related learning.
Cannabis Bioscience International Holdings (search), Inc. (OTCID: CBIH) has announced the completion of its patent-related scientific framework for PTSD (search)-focused research, centering on the interplay between cannabinoids and psilocybin in addressing trauma, memory, emotional regulation, and recovery. The Houston-based public company is positioning this work as part of a broader strategy to build a cross-category regulated medical research platform.
"PTSD (search) is not simply a market category. It is the veteran who comes home but never fully returns to peace. It is the child who carries abuse into adulthood. It is the woman rebuilding her life after violence. It is human suffering that deserves serious science," said Mr. John Jones, CBIH Treasurer, Director, and former 101st Airborne Division sergeant. "This work was developed with care, purpose, and compassion as part of our mission to build meaningful scientific assets for responsible trauma-related research."
The PTSD (search) Burden and Unmet Need
According to the U.S. Department of Veterans Affairs' National Center for PTSD (search), approximately 5% of U.S. adults experience PTSD in any given year, representing about 13 million Americans in 2020. The company notes that this figure may not fully capture those who remain undiagnosed, do not report symptoms, or lack access to care. The condition affects veterans, first responders, survivors of sexual assault and domestic violence, children exposed to trauma, families, and communities.
A Dual-Mechanism Scientific Rationale
CBIH's PTSD (search)-focused work is built on a key scientific premise: cannabinoids and psilocybin may address different but related dimensions of trauma biology. Cannabinoids may help support pathways associated with stress response, sleep, inflammation, emotional regulation, and the endocannabinoid system. Psilocybin, meanwhile, has shown encouraging potential in controlled clinical research related to neuroplasticity, emotional processing, fear-related learning, cognitive flexibility, and mood.
"The Company is building more than a portfolio of patent-related concepts; it is building a broader scientific foundation for cannabinoid-based biotechnology at a time when the cannabis sector is about to turn a corner from traditional market perceptions toward a new era defined by science, regulation, intellectual property, and medical innovation," said Dante Picazo, CEO of CBIH.
Intellectual Property Strategy and Platform Approach
The firm's intellectual property work is designed to support a cross-category regulated medical research platform beyond any single condition, product, or market category. By organizing its scientific ideas around cannabinoids, psilocybin, formulation systems, therapeutic pathways, and future medical applications, CBIH seeks to define, protect, and advance the scientific logic behind next-generation therapeutic development.
This PTSD (search) initiative forms part of CBIH's broader portfolio of 25 finalized patent applications, including 10 applications already submitted to the USPTO and 15 additional applications finalized and ready for submission. The portfolio covers neurological, autoimmune, oncological, metabolic, and other complex disease areas, within a larger body of more than 100 medical formulation intellectual property assets.
As cannabinoid- and psychedelic-related medicine moves toward a more regulated and research-driven future, CBIH is assembling scientific assets designed to give the company room to move, room to partner, and room to become a leading name within the emerging field of plant-derived therapeutic science.